Please wait
0001479615EX-FILING FEESOrdinary Shares, nominal value 0.05 per share, to be issued upon the exercise of options to be granted under the 2023 Equity Incentive Plan with Non-Employee Sub-Plan and CSOP Sub-Plan 0001479615 2025-02-27 2025-02-27 0001479615 1 2025-02-27 2025-02-27 iso4217:USD xbrli:pure xbrli:shares
Exhibit 107
Calculation of Filing Fee Table
Form
S-8
(Form Type)
Silence Therapeutics plc
(Exact Name of Registrant as Specified in its Charter)
Table 1 – Newly Registered Securities
                 
    
Security
Type
  
Security
Class
Title
(1)
  
Fee
 Calculation 
Rule
  
Amount
Registered
(2)
  
Proposed
 Maximum 
Offering
Price Per
Unit
  
Maximum
Aggregate
Offering
Price
  
Fee
Rate
  
Amount of
 Registration 
Fee
                 
Fees to be Paid   Equity  
Ordinary Shares, nominal value £0.05 per share, to be issued upon the exercise of options to be granted under the 2023 Equity Incentive Plan with
Non-Employee
Sub-Plan
and CSOP
Sub-Plan
   Other   9,194,183 
(4)
   $1.63
(3)
   $14,986,518.29   $0.0001531   $2,294.44
             
    Total Offering Amounts   9,194,183   —    $14,986,518.29   —    $2,294.44
             
    Total Fees Previously Paid     —    —    —    — 
             
    Total Fee Offsets     —    —    —    — 
             
    Net Fee Due       —    —    —    $2,294.44
 
  (1)
These shares may be represented by the Silence Therapeutics plc (the “
Registrant’s
”) American Depositary Shares (“
ADSs
”). Each ADS represents three ordinary shares, nominal value £0.05 per share (“
Ordinary Shares
”). The Registrant’s ADSs issuable upon deposit of the Ordinary Shares registered hereby have been registered under a separate registration statement on Form
F-6
(File
No. 333-248217).
 
  (2)
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “
Securities Act
”), this Registration Statement shall also cover any additional Ordinary Shares and ADSs of the Registrant that become issuable under the Registrant’s 2023 Equity Incentive Plan with
Non-Employee
Sub-Plan
and CSOP
Sub-Plan
(the “
2023 EIP
”) by reason of any share dividend, share split
(sub-division),
recapitalization or other similar transaction.
 
  (3)
Estimated in accordance with Rules 457(c) and 457(h) solely for purposes of calculating the registration fee on the basis of $1.63 per Ordinary Share (or $4.89 per ADS), the average of the high and low prices of the ADSs as reported on the Nasdaq Global Market on February 20, 2025.
 
  (4)
Represents (i) 5,666,963 additional Ordinary Shares that were automatically added to the shares authorized for issuance under the Registrant’s 2023 EIP on January 1, 2025 (the “
2025 Evergreen
”) and (ii) 3,527,220 additional Ordinary Shares that were automatically added to the shares authorized for issuance under the Registrant’s 2023 EIP on January 1, 2024 (the “
2024 Evergreen
”), in each case pursuant to an annual “evergreen” increase provision contained in the 2023 EIP. The number of shares reserved for issuance under the 2023 EIP will automatically increase on January 1st each year, starting on January 1, 2024, and continuing through January 1, 2033, by an amount which is the lesser of (a) five percent (5%) of the total number of Ordinary Shares of the Registrant outstanding on December 31st of the immediately preceding calendar year; and (b) a smaller number of shares determined by the Registrant’s board of directors.